Only two groups have ever received RAD140 in a published study: women with metastatic breast cancer, and healthy volunteers given microgram amounts so that anti-doping laboratories could learn to detect it. Neither group says what the compound does in a healthy man, which is the first thing to know about any RAD 140 study.
The breast-cancer trial enrolled 22 postmenopausal women, 100 mg once daily turned out to be the highest tolerated dose, liver function tests rose often, and benefit was modest, with tumour shrinkage or stable disease at 24 weeks in 18.2% of the women. Everything else known about the compound in humans comes from outside trials: beyond the trial record, published case reports add drug-induced liver injury and inflammation of cardiac muscle in young males exposed to products sold as RAD140, and outside the published trials falls in testosterone, the principal circulating androgen, are described, though no trial has measured serum testosterone in men.
Cancer was not the original idea. When RAD140 was characterised in preclinical models in 2011, it was as an orally bioavailable selective androgen receptor modulator (SARM): a non-steroidal agent that switches on androgen signalling strongly in some tissues and weakly in others. The switch it acts on is the androgen receptor, a protein inside cells that mediates the actions of androgens, and since that receptor is spread unevenly across tissues, the SARM class was designed to give skeletal muscle and bone the anabolic action without giving prostate tissue the androgenic one. Tissue selectivity of that kind is the heart of the RAD 140 mechanism of action.
Oncology took over because of what happened in breast cancer cells and mouse xenografts, where the SARM RAD140 activated the androgen receptor and suppressed tumours carrying both that receptor and the oestrogen receptor, the receptor that mediates oestrogen-driven growth of breast tumours. The RAD 140 human trials on record amount to the volunteer work and the two breast cancer studies.
How many patients were in the phase 1 trial?
Twenty-two postmenopausal women took part in the first-in-human phase 1 trial of RAD140, and 21 of their tumours were androgen-receptor-positive. All 22 had ER+/HER2- metastatic breast cancer, oestrogen-receptor-positive disease without HER2 amplification that had spread to distant sites, and all had been heavily pretreated: several earlier lines of therapy had already failed them.
Escalation followed a 3+3 dose escalation design, in which a dose level starts with a cohort of patients and gains a second cohort where dose-limiting toxicity appears, and the top level rested on three women in total. A pharmacokinetic expansion cohort ran alongside, an added group studied solely to measure the blood concentration of the compound over time. The aims the investigators set were safety, tolerability, the pharmacokinetic profile, any anti-tumour activity and the maximum tolerated dose. Six women were on 50 mg, 13 on 100 mg and three on 150 mg, each administered orally once daily.
The paper appeared in 2022, the first of the RAD 140 clinical trials to report in full. Its participants were older women with advanced, treatment-resistant disease, and its findings belong to that group rather than to healthy adults of either sex.
What was the maximum tolerated dose?
The answer for RAD140 is 100 mg once daily, and the word to weigh is tolerated. A maximum tolerated dose is not a dose shown to work. It is the level below the one at which dose-limiting toxicities clustered, carried forward because escalation halts there, and in this trial the level above 100 mg had gone to three women, no more; a ceiling resting on three patients is the standing limitation of escalation by threes.
The once-daily schedule had a pharmacokinetic reason, an elimination half-life of 44.7 hours. A RAD 140 half-life that long outruns the dosing interval, so concentrations accumulate over the first days of administration and exposure at steady state exceeds the exposure from any single dose. The trial’s one partial response, a shrinkage of the measured tumour by at least a prespecified proportion, came at 100 mg. What the 100 mg ceiling marks is the tolerance of women with metastatic cancer under close medical supervision, and nothing beyond it.
How the trial doses are described in discussions
The amounts administered in the phase 1 trial are described, beyond the trial data, as very high, in several accounts as extreme, and as given over months rather than weeks.
In descriptions beyond the trials, those daily amounts are read as evidence that the compound is well tolerated, a reading answered by pointing to the liver test results of the same trial. The accounts weigh the participants’ profile more heavily than the amounts, since older women with advanced cancer tolerating a dose says little about younger men, and they note that the company developing the compound funded the trial.
Liver tests and other adverse events in the first trial
The liver dominated the adverse events of the phase 1 trial. Rises in liver-related blood tests were the most frequent treatment-emergent adverse events (TEAE), which arise during treatment whether or not the treatment caused them: aspartate aminotransferase (AST) rose in 59.1% of the women and alanine aminotransferase (ALT) in 45.5%. Total bilirubin rose in 27.3%, and vomiting, dehydration, decreased appetite and decreased weight were each recorded at that same frequency; no other event passed the 10% reporting threshold.
Such a tally counts every event arising on treatment, and in metastatic disease that includes what the cancer itself produces, so severity was graded on the conventional scale, where 3 is severe and 4 life-threatening. Of the women enrolled, 16, or 72.7%, had an event of grade 3 or 4; the commonest, at 22.7% each, were the AST and ALT elevations and hypophosphataemia, a low concentration of phosphate in the blood. Events judged related to treatment occurred in 17 women, or 77.3%, seven of them (31.8%) at grade 3 and none at grade 4.
The investigators called the profile acceptable in metastatic breast cancer, weighing it against the prognosis of that disease rather than against a healthy baseline. Case-report authors later borrowed the same liver findings as the background to their own patients, and since the trial record and the case literature answer different questions, the wider pattern of RAD 140 side effects rests on both.
Did RAD140 shrink tumours, and how many patients benefited?
One tumour shrank. The phase 1 trial recorded its single partial response at 100 mg once daily, in a woman who carried an ESR1 mutation at baseline, an alteration in the gene encoding the oestrogen receptor; mutations of that gene commonly arise under endocrine therapy and reduce its efficacy, which is why the investigators noted the genotype beside the response. A partial response means the measured tumour shrank on imaging by at least a prespecified proportion of its size before treatment.
For the trial as a whole the clinical benefit rate at 24 weeks was 18.2%, counting tumour shrinkage or stable disease, and median progression-free survival (the time to disease progression or death) was 2.3 months. In women who had exhausted several lines of therapy, the investigators read those numbers as preliminary evidence of anti-tumour activity for RAD140, not as a demonstration of efficacy.
Markers of androgen receptor engagement in the trial
Blood told the investigators that the compound was acting. Sex hormone-binding globulin (SHBG) fell in all 18 women whose levels were measured, and prostate-specific antigen (PSA) rose in 16 of 20. Neither reading measures clinical benefit, because androgen receptor activity in women has no direct clinical readout; each served as a surrogate marker, a measurable stand-in for an effect that cannot be observed directly, and the fall in SHBG was the steadier of the two, since PSA did not rise in four of the 20 women tested.
Paired tumour biopsies, samples taken before and during treatment, went a step further and demonstrated target engagement, the proof that the compound had reached and acted on its receptor inside the tumour. A circulating marker shifts wherever androgen signalling is active; a biopsy places the effect in the trial’s target. Activation of the receptor in tumour cells was what the preclinical breast cancer models had predicted, and these markers establish that RAD140 activated the androgen receptor in the participants while leaving open whether that action helped them.
What the later vosilasarm study reported
Under the name vosilasarm and the code EP0062, its designation in the developer’s programme, the compound returned in a study that recorded elevated liver function tests at 10 mg twice daily. The participants again had advanced or metastatic breast cancer that was androgen-receptor-positive, oestrogen-receptor-positive and HER2-negative. The authors call the compound a first-in-class oral SARM and the design a phase 1/2 study, one protocol that joins dose finding to a first test of efficacy, the design chosen when a mechanism has already been shown because it shortens the path to efficacy testing.
All that exists of that study is a conference abstract, presented to the American Society of Clinical Oncology (ASCO) in 2025. A few hundred words cannot carry patient numbers, an escalation scheme or outcome data in the detail of the earlier full paper, yet the abstract is the most recent record of the compound in humans and so the source of new RAD-140 research. The first trial, by contrast, appeared as a full paper, and case-report authors soon began to cite its liver findings as context for their own patients.
Is RAD140 still in trials, and what phase has it reached?
Beyond the trial data, the RAD-140 clinical trials’ status in 2026 is the point raised most often, and the clinical programme is usually given as a single phase 1 study, sometimes as one still running.
In those accounts RAD140 is also the subject of a phase 1/2 study pairing it with endocrine therapy in breast cancer, while the existence of any phase 2 trial is treated as uncertain; a further trial is sometimes said to be about to begin, and that expectation is itself read as a sign of safety. The programme’s original purpose is occasionally given as the treatment of skeletal muscle wasting in patients with cancer rather than of the cancer itself, and the question left unanswered, beyond the trial data, is why RAD140 has still not been approved.
Studies that gave RAD140 to healthy volunteers
Healthy volunteers have received RAD140 only in microgram amounts, and only so that its detection could be worked out. Six such micro-dose excretion studies, each in five adult male volunteers, gave a single dose orally and analysed the urine by liquid chromatography coupled to high-resolution tandem mass spectrometry (LC-HRMS/MS). Several urinary metabolites, the breakdown products formed in the liver and excreted by the kidneys, were described in human urine for the first time, with elimination profiles and detection times for six of them and for the intact compound.
The question was forensic. A contaminated supplement can produce an adverse analytical finding, a positive doping control result, as readily as deliberate exposure can, so the metabolite ratios were tested for their power to tell the two apart, and those metabolites and ratios are what a laboratory looks for when it runs a RAD 140 drug test.
A companion study applied 10 or 50 micrograms to the skin of the lower forearm, five volunteers at each amount: after 10 micrograms the compound appeared in the urine of one of the five, after 50 micrograms in all five, for up to nine days. A laboratory comparison of metabolism models found 16 metabolites in a real doping control urine sample positive for the compound, and liver spheroids on an organ-on-a-chip platform reproduced 14 of them. Detection was the whole object of this work; none of it measured an effect on tissue.
What case reports outside the trials describe
The remaining human data are case reports of single patients, mostly young men exposed to products sold as RAD140, in which the compound is blamed by exclusion rather than by measurement. An inpatient work-up in a 26-year-old man with acute drug-induced liver injury found no other cause; in a 22-year-old the viral hepatitis, autoimmune and metabolic panels were unremarkable and endoscopic cholangiopancreatography found no obstruction. Measurement is what the batch and purity data of the RAD-140 for sale here supply for laboratory work.
The reports share a pattern, cholestatic drug-induced liver injury, in which bile flow is impaired and bilirubin builds up in the blood. The highest bilirubin, a peak total of 38.5 mg/dL, was in a 24-year-old exposed for five weeks, whose biopsy showed canalicular cholestasis and minimal portal inflammation; the 22-year-old, exposed for 16 weeks, had mixed portal hepatitis with cholestasis and biliary reactive changes on biopsy. A 29-year-old came to hospital with jaundice, the yellowing of skin and eyes from retained bilirubin, after three months of exposure, and the injury in the 26-year-old was classed as idiosyncratic, unpredictable and independent of dose.
Severe drug-induced liver injury has been reported in a further young man and prolonged cholestasis requiring corticosteroid treatment in another, and the pattern reaches beyond RAD140: LiverTox, the National Institutes of Health database on drug-induced liver injury, lists cholestatic drug-induced liver injury for SARMs as a class. Cardiac reports are fewer and come on earlier. A young man developed possible acute myocarditis, inflammation of cardiac muscle, after exposure to RAD-140; a 16-year-old boy developed myopericarditis, inflammation of cardiac muscle and the pericardium around it, after a first dose; heart failure has been attributed to the compound in a further patient. Each report shows a possible link in one patient and never a rate, because nobody knows the size of the exposed population.
Did the liver enzyme rises reverse after stopping?
In the published cases they did, over weeks to months, with one patient who needed intensive care, a course set out under RAD140 and the liver.
Reports where the product also held andarine, LGD-4033 or MK-677
Where a product held more than one compound, RAD140 cannot be singled out as the cause, and several of the published cases are of that kind. The most severe case of drug-induced liver injury on record followed a supplement combining RAD-140 with andarine (S-4), a second non-steroidal SARM. The 52-year-old’s drug-induced liver injury followed two products, the second containing LGD-4033 (ligandrol), another member of the SARM class and itself the subject of case reports of drug-induced liver injury; his recovery once both products stopped is told with the other recoveries.
The spleen gives the one case outside the liver: a spontaneous splenic rupture, a tear of the spleen without trauma, in a 54-year-old man during exposure to RAD-140 together with MK-677 (ibutamoren), a growth hormone secretagogue rather than a SARM. Any causal role is speculative in the authors’ view, because histology raised the possibility of a pre-existing vascular malformation. The same secretagogue turns up again in the supplements of a 40-year-old man, with cardarine, a further compound declared on their labels.
Does RAD140 lower testosterone in humans?
In men, nobody has measured what RAD140 does to testosterone. The only patient trial enrolled postmenopausal women and followed SHBG and PSA rather than serum testosterone; the fall in SHBG in every woman tested and the rise in PSA are signs of androgen receptor activity, not measurements of gonadal hormone output. The human record therefore leaves RAD-140 testosterone suppression in men unmeasured, with those markers as all it offers.
One published male case comes close, and the page on the testes tells it in full: a 40-year-old with bilateral gynaecomastia and biochemical hypogonadotropic hypogonadism, a pattern that places the origin of the suppression above the testes rather than in them. It isolates nothing, because his supplements also held undisclosed testosterone, oestradiol and growth hormone beside the declared RAD-140, MK-677 and cardarine, and both the gynaecomastia and the hormone profile resolved fully after cessation. Neither source shows what the compound itself does to testosterone in men.
Testosterone suppression as described in discussions
Testosterone suppression is described, outside the trial record, mainly through animal findings. The study quoted most often, beyond the trial data, is one in monkeys in which a very low amount relative to body weight brought a marked fall in testosterone, and it is treated as a warning for men; beside it stands a second animal finding in which testosterone fell to a similarly low level in every dose group after some weeks of exposure. In those accounts the degree of suppression is compared with that of the older anabolic-androgenic steroids.
Does RAD140 increase muscle mass in humans, and has it been tested for muscle wasting?
RAD140 has not been shown to increase muscle mass in humans. Both trials on record were breast cancer trials with oncology endpoints, neither measured muscle or tested a condition of skeletal muscle loss, and in the first the weight-related signals ran the other way, with decreased weight and decreased appetite among the adverse events.
Muscle wasting disorders are nonetheless the stated rationale of the SARM class. The conditions named for it were general sarcopenia, cancer cachexia and the muscular dystrophies: the age-related loss of skeletal muscle mass and strength, the wasting syndrome of advanced malignancy, and the inherited dystrophies. None had become an approved indication when SARMs entered doping control programmes, so RAD 140 and muscle wasting disorders are linked through that class rationale and not through any trial of the compound.
The animal data are mixed rather than uniformly anabolic. In young male rats, RAD140 alone raised fibre cross-sectional area in the plantaris significantly over vehicle controls, yet added nothing statistically over functional overload alone, the surgical removal of synergists that forces the remaining muscle to carry the load, and tibial cortical and trabecular bone were unchanged after 14 days.
In mice of 23 to 25 months, the compound preserved lean mass and bone mineral density in males but not in females at 5 mg/kg daily for six weeks, while frailty scores and grip strength were unaffected in both sexes. The longest study, ten weeks at the same amount in female mice, found frailty status and mortality risk increased and no improvement in strength. Each RAD-140 skeletal muscle study in the record therefore reads as sex- and age-dependent, against an early characterisation that reported anabolic activity in androgen-sensitive tissue.
Rat muscle findings as described in discussions
In descriptions beyond the trials, the early rat work is the usual authority for an anabolic claim: the compound is said to have matched the effect of testosterone on skeletal muscle while acting far less on prostate tissue, and a related claim, that a much lower amount delivered most of the effect of a higher one, is described widely.
In those accounts the origin of the programme is given as muscle wasting, or as replacing testosterone in men, and against such claims the species itself stands as the caveat, since the animals in question were rats.
The breast-cancer models behind the trials
Women with androgen-receptor-positive and oestrogen-receptor-positive tumours were enrolled because that is where the preclinical work pointed. RAD140 bound the androgen receptor with high affinity and specificity and activated it in breast cancer cells while leaving prostate cancer cells unactivated; it suppressed the oestrogen receptor pathway, including expression of the ESR1 gene; and, administered orally, it inhibited the growth of patient-derived xenografts (PDX), tumour fragments taken from patients and grown in immunodeficient mice. With palbociclib, an inhibitor of cyclin-dependent kinases 4 and 6 used in oestrogen-receptor-positive disease, it worked better in those models than alone.
Later RAD-140 breast cancer research sharpened the conditions for that logic. The androgen receptor is present in 80% to 90% of oestrogen-receptor-positive breast cancers. Where its level was high, the compound activated androgen signalling and suppressed tumour growth by deregulating oestrogen receptor expression and blocking its function; where its level was low, the androgen receptor blocker enzalutamide acted directly on the oestrogen receptor and worked instead.
The reading was that the AR/ER ratio, the balance between androgen and oestrogen receptor levels in a tumour, decides the direction of receptor targeting. Potent and orally bioavailable from its first characterisation, the compound was the obvious candidate for the agonist side of that balance.
Brain and heart findings in animal studies
Two lines of animal work have nothing to do with oncology. In the first, RAD140 was as effective as testosterone at reducing cell death from apoptotic insults in cultured rat hippocampal neurons, a protection that depended on MAPK signalling, since an inhibitor of that cascade abolished it; in gonadectomised adult male rats the compound reduced hippocampal neuron loss in the kainate lesion model, which kills neurons with a systemic excitotoxin, while largely sparing prostate tissue. The authors read this work on RAD140 and the brain as preclinical evidence relevant to Alzheimer’s disease research.
The second line measured cardiac function in 23-month-old mice given 5 mg/kg daily for six weeks. Treated animals of both sexes had an ejection fraction 10.4% higher than controls, a stroke volume 9.6 µL higher and a cardiac output 4.5 mL/min higher; myocardial strain and isovolumic relaxation time improved in males, with lesser or opposite changes in females, and no structural differences were observed. Neither the neuroprotection in rats nor the cardiac changes in mice have been tested in humans.
Where RAD140 stands with regulators and anti-doping rules
RAD-140 (testolone) is an investigational selective androgen receptor modulator, still under clinical study and licensed for no indication, and as of 2018 no SARM had received full clinical approval. The case-report literature records the same position for the United States, describing such compounds as not approved by the US Food and Drug Administration (FDA).
Sport settled its position long ago. SARMs joined the World Anti-Doping Agency (WADA) Prohibited List in 2008 for their anabolic action on skeletal muscle and bone, and they sit under section S1.2 of that list, other anabolic agents, prohibited at all times, in and out of competition. Because the compound is specifically prohibited for athletes at all times, the micro-dose excretion studies were commissioned to serve doping control. The legal position in the United Kingdom lies outside this article.
Limits of the trial evidence
On every axis the evidence is narrow. One RAD 140 study has reported in full, in 22 heavily pretreated postmenopausal women with metastatic breast cancer, with dose groups as small as three women; the only later study is known from a short abstract, so its patient numbers and outcomes cannot be weighed against it; and neither study enrolled men or healthy adults at therapeutic amounts or carried a skeletal muscle or testosterone endpoint.
The volunteer studies measured detection rather than any effect on tissue, and the case reports describe single patients, often after mixed or mislabelled products. The animal results diverge by sex and age, with lean mass preserved in older males while frailty and mortality risk rose in females at the same daily amount, which suggests that the effects of the compound depend on the population tested; no figure from one group can be read across to another. Our SARMs for sale in the UK carry batch numbers and purity data for that reason.
Outside the published trials, three further matters recur in what this article has reported: the fall in testosterone in monkeys, the comparison with testosterone in rats, and the claim that a far lower amount gives most of the effect of a higher one. No published scientific inquiry into RAD-140 among this article’s sources has measured them.
What the trials administered and what a bottle sold as RAD140 contains are two different questions, since analytical surveys found Under-strength RAD 140 products and labels that left compounds out.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
Which adverse events were the most frequent in the first human trial of RAD140?
Rises in liver-related blood tests ✓
Vomiting, dehydration and appetite loss
Low phosphate levels in the blood
Falls in serum testosterone
AST rose in 59.1% and ALT in 45.5% of the women, ahead of vomiting, dehydration and every other recorded event.
Who were enrolled in the first-in-human trial of RAD140?
Healthy young men in a muscle-building study
Postmenopausal women with metastatic breast cancer ✓
Patients with muscle wasting from advanced cancer
Older men with age-related falls in testosterone levels
All 22 participants were heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, so the results say little about men or healthy adults.
How many women in the phase 1 trial had a partial response, a measured shrinkage of the tumour?
Four women of the 22 enrolled
Eleven women of the 22 enrolled
A single woman of the 22 enrolled ✓
Seventeen women of the 22 enrolled
One woman, carrying an ESR1 mutation, had a partial response; the 18.2% benefit rate at 24 weeks also counted stable disease.
What did analysts find in four Slovak online supplements whose labels declared testolone?
Twice the amount of compound stated on the label
Ostarine found in place of the declared testolone
No reliable identification of the declared compound ✓
Undeclared testosterone and oestradiol beside the compound
Raman spectroscopy confirmed SARMs in nine of 16 supplements, but the four samples labelled testolone gave no reliable identification of it.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Michael S. Yule is a general surgery registrar at the Edinburgh Cancer Research Centre, University of Edinburgh. Michael specialises in oncology and cancer cachexia.
RAD 140 before and after accounts report rises in body weight and strength, but no study has measured how much is muscle or what remains after exposure.
Enobosarm FDA status: no approval, as lung-cancer trials missed their endpoints, breast-cancer trials stopped early and a semaglutide trial is ongoing.
What does RAD-140 do to the brain is known only from nerve-cell and rat studies, where it shielded neurons from injury about as well as testosterone did.
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD 140 study: what the breast-cancer trials found
By Laura Walker, PhD · Reviewed by Michael S. Yule
Published · Updated · 21 min read
What RAD140 has been tested for in humans
Only two groups have ever received RAD140 in a published study: women with metastatic breast cancer, and healthy volunteers given microgram amounts so that anti-doping laboratories could learn to detect it. Neither group says what the compound does in a healthy man, which is the first thing to know about any RAD 140 study.
The breast-cancer trial enrolled 22 postmenopausal women, 100 mg once daily turned out to be the highest tolerated dose, liver function tests rose often, and benefit was modest, with tumour shrinkage or stable disease at 24 weeks in 18.2% of the women. Everything else known about the compound in humans comes from outside trials: beyond the trial record, published case reports add drug-induced liver injury and inflammation of cardiac muscle in young males exposed to products sold as RAD140, and outside the published trials falls in testosterone, the principal circulating androgen, are described, though no trial has measured serum testosterone in men.
Cancer was not the original idea. When RAD140 was characterised in preclinical models in 2011, it was as an orally bioavailable selective androgen receptor modulator (SARM): a non-steroidal agent that switches on androgen signalling strongly in some tissues and weakly in others. The switch it acts on is the androgen receptor, a protein inside cells that mediates the actions of androgens, and since that receptor is spread unevenly across tissues, the SARM class was designed to give skeletal muscle and bone the anabolic action without giving prostate tissue the androgenic one. Tissue selectivity of that kind is the heart of the RAD 140 mechanism of action.
Oncology took over because of what happened in breast cancer cells and mouse xenografts, where the SARM RAD140 activated the androgen receptor and suppressed tumours carrying both that receptor and the oestrogen receptor, the receptor that mediates oestrogen-driven growth of breast tumours. The RAD 140 human trials on record amount to the volunteer work and the two breast cancer studies.
How many patients were in the phase 1 trial?
Twenty-two postmenopausal women took part in the first-in-human phase 1 trial of RAD140, and 21 of their tumours were androgen-receptor-positive. All 22 had ER+/HER2- metastatic breast cancer, oestrogen-receptor-positive disease without HER2 amplification that had spread to distant sites, and all had been heavily pretreated: several earlier lines of therapy had already failed them.
Escalation followed a 3+3 dose escalation design, in which a dose level starts with a cohort of patients and gains a second cohort where dose-limiting toxicity appears, and the top level rested on three women in total. A pharmacokinetic expansion cohort ran alongside, an added group studied solely to measure the blood concentration of the compound over time. The aims the investigators set were safety, tolerability, the pharmacokinetic profile, any anti-tumour activity and the maximum tolerated dose. Six women were on 50 mg, 13 on 100 mg and three on 150 mg, each administered orally once daily.
The paper appeared in 2022, the first of the RAD 140 clinical trials to report in full. Its participants were older women with advanced, treatment-resistant disease, and its findings belong to that group rather than to healthy adults of either sex.
What was the maximum tolerated dose?
The answer for RAD140 is 100 mg once daily, and the word to weigh is tolerated. A maximum tolerated dose is not a dose shown to work. It is the level below the one at which dose-limiting toxicities clustered, carried forward because escalation halts there, and in this trial the level above 100 mg had gone to three women, no more; a ceiling resting on three patients is the standing limitation of escalation by threes.
The once-daily schedule had a pharmacokinetic reason, an elimination half-life of 44.7 hours. A RAD 140 half-life that long outruns the dosing interval, so concentrations accumulate over the first days of administration and exposure at steady state exceeds the exposure from any single dose. The trial’s one partial response, a shrinkage of the measured tumour by at least a prespecified proportion, came at 100 mg. What the 100 mg ceiling marks is the tolerance of women with metastatic cancer under close medical supervision, and nothing beyond it.
How the trial doses are described in discussions
The amounts administered in the phase 1 trial are described, beyond the trial data, as very high, in several accounts as extreme, and as given over months rather than weeks.
In descriptions beyond the trials, those daily amounts are read as evidence that the compound is well tolerated, a reading answered by pointing to the liver test results of the same trial. The accounts weigh the participants’ profile more heavily than the amounts, since older women with advanced cancer tolerating a dose says little about younger men, and they note that the company developing the compound funded the trial.
Liver tests and other adverse events in the first trial
The liver dominated the adverse events of the phase 1 trial. Rises in liver-related blood tests were the most frequent treatment-emergent adverse events (TEAE), which arise during treatment whether or not the treatment caused them: aspartate aminotransferase (AST) rose in 59.1% of the women and alanine aminotransferase (ALT) in 45.5%. Total bilirubin rose in 27.3%, and vomiting, dehydration, decreased appetite and decreased weight were each recorded at that same frequency; no other event passed the 10% reporting threshold.
Such a tally counts every event arising on treatment, and in metastatic disease that includes what the cancer itself produces, so severity was graded on the conventional scale, where 3 is severe and 4 life-threatening. Of the women enrolled, 16, or 72.7%, had an event of grade 3 or 4; the commonest, at 22.7% each, were the AST and ALT elevations and hypophosphataemia, a low concentration of phosphate in the blood. Events judged related to treatment occurred in 17 women, or 77.3%, seven of them (31.8%) at grade 3 and none at grade 4.
The investigators called the profile acceptable in metastatic breast cancer, weighing it against the prognosis of that disease rather than against a healthy baseline. Case-report authors later borrowed the same liver findings as the background to their own patients, and since the trial record and the case literature answer different questions, the wider pattern of RAD 140 side effects rests on both.
Did RAD140 shrink tumours, and how many patients benefited?
One tumour shrank. The phase 1 trial recorded its single partial response at 100 mg once daily, in a woman who carried an ESR1 mutation at baseline, an alteration in the gene encoding the oestrogen receptor; mutations of that gene commonly arise under endocrine therapy and reduce its efficacy, which is why the investigators noted the genotype beside the response. A partial response means the measured tumour shrank on imaging by at least a prespecified proportion of its size before treatment.
For the trial as a whole the clinical benefit rate at 24 weeks was 18.2%, counting tumour shrinkage or stable disease, and median progression-free survival (the time to disease progression or death) was 2.3 months. In women who had exhausted several lines of therapy, the investigators read those numbers as preliminary evidence of anti-tumour activity for RAD140, not as a demonstration of efficacy.
Markers of androgen receptor engagement in the trial
Blood told the investigators that the compound was acting. Sex hormone-binding globulin (SHBG) fell in all 18 women whose levels were measured, and prostate-specific antigen (PSA) rose in 16 of 20. Neither reading measures clinical benefit, because androgen receptor activity in women has no direct clinical readout; each served as a surrogate marker, a measurable stand-in for an effect that cannot be observed directly, and the fall in SHBG was the steadier of the two, since PSA did not rise in four of the 20 women tested.
Paired tumour biopsies, samples taken before and during treatment, went a step further and demonstrated target engagement, the proof that the compound had reached and acted on its receptor inside the tumour. A circulating marker shifts wherever androgen signalling is active; a biopsy places the effect in the trial’s target. Activation of the receptor in tumour cells was what the preclinical breast cancer models had predicted, and these markers establish that RAD140 activated the androgen receptor in the participants while leaving open whether that action helped them.
What the later vosilasarm study reported
Under the name vosilasarm and the code EP0062, its designation in the developer’s programme, the compound returned in a study that recorded elevated liver function tests at 10 mg twice daily. The participants again had advanced or metastatic breast cancer that was androgen-receptor-positive, oestrogen-receptor-positive and HER2-negative. The authors call the compound a first-in-class oral SARM and the design a phase 1/2 study, one protocol that joins dose finding to a first test of efficacy, the design chosen when a mechanism has already been shown because it shortens the path to efficacy testing.
All that exists of that study is a conference abstract, presented to the American Society of Clinical Oncology (ASCO) in 2025. A few hundred words cannot carry patient numbers, an escalation scheme or outcome data in the detail of the earlier full paper, yet the abstract is the most recent record of the compound in humans and so the source of new RAD-140 research. The first trial, by contrast, appeared as a full paper, and case-report authors soon began to cite its liver findings as context for their own patients.
Is RAD140 still in trials, and what phase has it reached?
Beyond the trial data, the RAD-140 clinical trials’ status in 2026 is the point raised most often, and the clinical programme is usually given as a single phase 1 study, sometimes as one still running.
In those accounts RAD140 is also the subject of a phase 1/2 study pairing it with endocrine therapy in breast cancer, while the existence of any phase 2 trial is treated as uncertain; a further trial is sometimes said to be about to begin, and that expectation is itself read as a sign of safety. The programme’s original purpose is occasionally given as the treatment of skeletal muscle wasting in patients with cancer rather than of the cancer itself, and the question left unanswered, beyond the trial data, is why RAD140 has still not been approved.
Studies that gave RAD140 to healthy volunteers
Healthy volunteers have received RAD140 only in microgram amounts, and only so that its detection could be worked out. Six such micro-dose excretion studies, each in five adult male volunteers, gave a single dose orally and analysed the urine by liquid chromatography coupled to high-resolution tandem mass spectrometry (LC-HRMS/MS). Several urinary metabolites, the breakdown products formed in the liver and excreted by the kidneys, were described in human urine for the first time, with elimination profiles and detection times for six of them and for the intact compound.
The question was forensic. A contaminated supplement can produce an adverse analytical finding, a positive doping control result, as readily as deliberate exposure can, so the metabolite ratios were tested for their power to tell the two apart, and those metabolites and ratios are what a laboratory looks for when it runs a RAD 140 drug test.
A companion study applied 10 or 50 micrograms to the skin of the lower forearm, five volunteers at each amount: after 10 micrograms the compound appeared in the urine of one of the five, after 50 micrograms in all five, for up to nine days. A laboratory comparison of metabolism models found 16 metabolites in a real doping control urine sample positive for the compound, and liver spheroids on an organ-on-a-chip platform reproduced 14 of them. Detection was the whole object of this work; none of it measured an effect on tissue.
What case reports outside the trials describe
The remaining human data are case reports of single patients, mostly young men exposed to products sold as RAD140, in which the compound is blamed by exclusion rather than by measurement. An inpatient work-up in a 26-year-old man with acute drug-induced liver injury found no other cause; in a 22-year-old the viral hepatitis, autoimmune and metabolic panels were unremarkable and endoscopic cholangiopancreatography found no obstruction. Measurement is what the batch and purity data of the RAD-140 for sale here supply for laboratory work.
The reports share a pattern, cholestatic drug-induced liver injury, in which bile flow is impaired and bilirubin builds up in the blood. The highest bilirubin, a peak total of 38.5 mg/dL, was in a 24-year-old exposed for five weeks, whose biopsy showed canalicular cholestasis and minimal portal inflammation; the 22-year-old, exposed for 16 weeks, had mixed portal hepatitis with cholestasis and biliary reactive changes on biopsy. A 29-year-old came to hospital with jaundice, the yellowing of skin and eyes from retained bilirubin, after three months of exposure, and the injury in the 26-year-old was classed as idiosyncratic, unpredictable and independent of dose.
Severe drug-induced liver injury has been reported in a further young man and prolonged cholestasis requiring corticosteroid treatment in another, and the pattern reaches beyond RAD140: LiverTox, the National Institutes of Health database on drug-induced liver injury, lists cholestatic drug-induced liver injury for SARMs as a class. Cardiac reports are fewer and come on earlier. A young man developed possible acute myocarditis, inflammation of cardiac muscle, after exposure to RAD-140; a 16-year-old boy developed myopericarditis, inflammation of cardiac muscle and the pericardium around it, after a first dose; heart failure has been attributed to the compound in a further patient. Each report shows a possible link in one patient and never a rate, because nobody knows the size of the exposed population.
Did the liver enzyme rises reverse after stopping?
In the published cases they did, over weeks to months, with one patient who needed intensive care, a course set out under RAD140 and the liver.
Reports where the product also held andarine, LGD-4033 or MK-677
Where a product held more than one compound, RAD140 cannot be singled out as the cause, and several of the published cases are of that kind. The most severe case of drug-induced liver injury on record followed a supplement combining RAD-140 with andarine (S-4), a second non-steroidal SARM. The 52-year-old’s drug-induced liver injury followed two products, the second containing LGD-4033 (ligandrol), another member of the SARM class and itself the subject of case reports of drug-induced liver injury; his recovery once both products stopped is told with the other recoveries.
The spleen gives the one case outside the liver: a spontaneous splenic rupture, a tear of the spleen without trauma, in a 54-year-old man during exposure to RAD-140 together with MK-677 (ibutamoren), a growth hormone secretagogue rather than a SARM. Any causal role is speculative in the authors’ view, because histology raised the possibility of a pre-existing vascular malformation. The same secretagogue turns up again in the supplements of a 40-year-old man, with cardarine, a further compound declared on their labels.
Does RAD140 lower testosterone in humans?
In men, nobody has measured what RAD140 does to testosterone. The only patient trial enrolled postmenopausal women and followed SHBG and PSA rather than serum testosterone; the fall in SHBG in every woman tested and the rise in PSA are signs of androgen receptor activity, not measurements of gonadal hormone output. The human record therefore leaves RAD-140 testosterone suppression in men unmeasured, with those markers as all it offers.
One published male case comes close, and the page on the testes tells it in full: a 40-year-old with bilateral gynaecomastia and biochemical hypogonadotropic hypogonadism, a pattern that places the origin of the suppression above the testes rather than in them. It isolates nothing, because his supplements also held undisclosed testosterone, oestradiol and growth hormone beside the declared RAD-140, MK-677 and cardarine, and both the gynaecomastia and the hormone profile resolved fully after cessation. Neither source shows what the compound itself does to testosterone in men.
Testosterone suppression as described in discussions
Testosterone suppression is described, outside the trial record, mainly through animal findings. The study quoted most often, beyond the trial data, is one in monkeys in which a very low amount relative to body weight brought a marked fall in testosterone, and it is treated as a warning for men; beside it stands a second animal finding in which testosterone fell to a similarly low level in every dose group after some weeks of exposure. In those accounts the degree of suppression is compared with that of the older anabolic-androgenic steroids.
Does RAD140 increase muscle mass in humans, and has it been tested for muscle wasting?
RAD140 has not been shown to increase muscle mass in humans. Both trials on record were breast cancer trials with oncology endpoints, neither measured muscle or tested a condition of skeletal muscle loss, and in the first the weight-related signals ran the other way, with decreased weight and decreased appetite among the adverse events.
Muscle wasting disorders are nonetheless the stated rationale of the SARM class. The conditions named for it were general sarcopenia, cancer cachexia and the muscular dystrophies: the age-related loss of skeletal muscle mass and strength, the wasting syndrome of advanced malignancy, and the inherited dystrophies. None had become an approved indication when SARMs entered doping control programmes, so RAD 140 and muscle wasting disorders are linked through that class rationale and not through any trial of the compound.
The animal data are mixed rather than uniformly anabolic. In young male rats, RAD140 alone raised fibre cross-sectional area in the plantaris significantly over vehicle controls, yet added nothing statistically over functional overload alone, the surgical removal of synergists that forces the remaining muscle to carry the load, and tibial cortical and trabecular bone were unchanged after 14 days.
In mice of 23 to 25 months, the compound preserved lean mass and bone mineral density in males but not in females at 5 mg/kg daily for six weeks, while frailty scores and grip strength were unaffected in both sexes. The longest study, ten weeks at the same amount in female mice, found frailty status and mortality risk increased and no improvement in strength. Each RAD-140 skeletal muscle study in the record therefore reads as sex- and age-dependent, against an early characterisation that reported anabolic activity in androgen-sensitive tissue.
Rat muscle findings as described in discussions
In descriptions beyond the trials, the early rat work is the usual authority for an anabolic claim: the compound is said to have matched the effect of testosterone on skeletal muscle while acting far less on prostate tissue, and a related claim, that a much lower amount delivered most of the effect of a higher one, is described widely.
In those accounts the origin of the programme is given as muscle wasting, or as replacing testosterone in men, and against such claims the species itself stands as the caveat, since the animals in question were rats.
The breast-cancer models behind the trials
Women with androgen-receptor-positive and oestrogen-receptor-positive tumours were enrolled because that is where the preclinical work pointed. RAD140 bound the androgen receptor with high affinity and specificity and activated it in breast cancer cells while leaving prostate cancer cells unactivated; it suppressed the oestrogen receptor pathway, including expression of the ESR1 gene; and, administered orally, it inhibited the growth of patient-derived xenografts (PDX), tumour fragments taken from patients and grown in immunodeficient mice. With palbociclib, an inhibitor of cyclin-dependent kinases 4 and 6 used in oestrogen-receptor-positive disease, it worked better in those models than alone.
Later RAD-140 breast cancer research sharpened the conditions for that logic. The androgen receptor is present in 80% to 90% of oestrogen-receptor-positive breast cancers. Where its level was high, the compound activated androgen signalling and suppressed tumour growth by deregulating oestrogen receptor expression and blocking its function; where its level was low, the androgen receptor blocker enzalutamide acted directly on the oestrogen receptor and worked instead.
The reading was that the AR/ER ratio, the balance between androgen and oestrogen receptor levels in a tumour, decides the direction of receptor targeting. Potent and orally bioavailable from its first characterisation, the compound was the obvious candidate for the agonist side of that balance.
Brain and heart findings in animal studies
Two lines of animal work have nothing to do with oncology. In the first, RAD140 was as effective as testosterone at reducing cell death from apoptotic insults in cultured rat hippocampal neurons, a protection that depended on MAPK signalling, since an inhibitor of that cascade abolished it; in gonadectomised adult male rats the compound reduced hippocampal neuron loss in the kainate lesion model, which kills neurons with a systemic excitotoxin, while largely sparing prostate tissue. The authors read this work on RAD140 and the brain as preclinical evidence relevant to Alzheimer’s disease research.
The second line measured cardiac function in 23-month-old mice given 5 mg/kg daily for six weeks. Treated animals of both sexes had an ejection fraction 10.4% higher than controls, a stroke volume 9.6 µL higher and a cardiac output 4.5 mL/min higher; myocardial strain and isovolumic relaxation time improved in males, with lesser or opposite changes in females, and no structural differences were observed. Neither the neuroprotection in rats nor the cardiac changes in mice have been tested in humans.
Where RAD140 stands with regulators and anti-doping rules
RAD-140 (testolone) is an investigational selective androgen receptor modulator, still under clinical study and licensed for no indication, and as of 2018 no SARM had received full clinical approval. The case-report literature records the same position for the United States, describing such compounds as not approved by the US Food and Drug Administration (FDA).
Sport settled its position long ago. SARMs joined the World Anti-Doping Agency (WADA) Prohibited List in 2008 for their anabolic action on skeletal muscle and bone, and they sit under section S1.2 of that list, other anabolic agents, prohibited at all times, in and out of competition. Because the compound is specifically prohibited for athletes at all times, the micro-dose excretion studies were commissioned to serve doping control. The legal position in the United Kingdom lies outside this article.
Limits of the trial evidence
On every axis the evidence is narrow. One RAD 140 study has reported in full, in 22 heavily pretreated postmenopausal women with metastatic breast cancer, with dose groups as small as three women; the only later study is known from a short abstract, so its patient numbers and outcomes cannot be weighed against it; and neither study enrolled men or healthy adults at therapeutic amounts or carried a skeletal muscle or testosterone endpoint.
The volunteer studies measured detection rather than any effect on tissue, and the case reports describe single patients, often after mixed or mislabelled products. The animal results diverge by sex and age, with lean mass preserved in older males while frailty and mortality risk rose in females at the same daily amount, which suggests that the effects of the compound depend on the population tested; no figure from one group can be read across to another. Our SARMs for sale in the UK carry batch numbers and purity data for that reason.
Outside the published trials, three further matters recur in what this article has reported: the fall in testosterone in monkeys, the comparison with testosterone in rats, and the claim that a far lower amount gives most of the effect of a higher one. No published scientific inquiry into RAD-140 among this article’s sources has measured them.
What the trials administered and what a bottle sold as RAD140 contains are two different questions, since analytical surveys found Under-strength RAD 140 products and labels that left compounds out.
Check what you remember
4 questions on this article; the right answer is marked.
AST rose in 59.1% and ALT in 45.5% of the women, ahead of vomiting, dehydration and every other recorded event.
All 22 participants were heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, so the results say little about men or healthy adults.
One woman, carrying an ESR1 mutation, had a partial response; the 18.2% benefit rate at 24 weeks also counted stable disease.
Raman spectroscopy confirmed SARMs in nine of 16 supplements, but the four samples labelled testolone gave no reliable identification of it.
Laura Walker, PhD · Newcastle University
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Michael S. Yule · University of Edinburgh · Last reviewed
General Surgery Registrar
Michael S. Yule is a general surgery registrar at the Edinburgh Cancer Research Centre, University of Edinburgh. Michael specialises in oncology and cancer cachexia.
Related Posts
RAD 140 before and after: muscle, strength and what lasts
RAD 140 before and after accounts report rises in body weight and strength, but no study has measured how much is muscle or what remains after exposure.
Enobosarm FDA: approval status and the trials in 2026
Enobosarm FDA status: no approval, as lung-cancer trials missed their endpoints, breast-cancer trials stopped early and a semaglutide trial is ongoing.
What does RAD-140 do to the brain? Neuron and rat studies
What does RAD-140 do to the brain is known only from nerve-cell and rat studies, where it shielded neurons from injury about as well as testosterone did.
Ostarine for cutting: lean mass and fat loss in the trials
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.